ProNAi Therapeutics - Employing DNA to Silence Disease
PNT2258 is one of the first systemically delivered DNAi therapeutics in a very ... The company's lead drug candidate, PNT2258, which has demonstrated in vivo ...ProNAi Therapeutics - Employing DNA to Silence Disease
... developed its first drug candidate, PNT2258, to Phase 1 clinical development The ... Advanced PNT2258, its lead drug product candidate, from discovery to IND ...Article : Improving Yields in Oligo Manufacturing Genetic Engineering ...
Article : Improving Yields in Oligo Manufacturing Genetic Engineering & Biotechnology News ... The company plans to file an IND for PNT2258 in August. ...News: ProNAi Assigns Polymun as Manufacturer of DNAi-based Cancer ...
ProNAi Therapeutics signed a supply agreement with Polymun Scientific to manufacture the company's PNT2258 DNAi®-based cancer therapeutic. Polymun will use its ...PipelineReview.com - Biotech News & Online Store - Pronai Therapeutics ...
PipelineReview.com is the Biotech News Center and Online Store of La Merie ... The company's lead drug candidate, PNT2258, which has demonstrated in vivo ...Sigvion Capital - View Article
The company's lead DNAi agent, PNT2258, will enter Phase I testing for cancer early next year. ... PNT2258 has shown activity when combined with Rituxan ...